Stock KRBP KIROMIC BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kiromic BioPharma, Inc.

Equities

KRBP

US4976342042

Delayed OTC Markets
Other stock markets
 09:46:23 01/07/2024 pm IST 		5-day change 1st Jan Change
2 USD -8.68% Intraday chart for Kiromic BioPharma, Inc. -20.00% +129.89%
20/06 Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial CI
07/06 Kiromic Biopharma, Inc. Issues 25% Senior Secured Convertible Promissory Note CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
BU
Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial
CI
Kiromic Biopharma, Inc. Issues 25% Senior Secured Convertible Promissory Note
CI
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
BU
Kiromic BioPharma, Inc. announced that it has received $2 million in funding
CI
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
BU
Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
CI
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
BU
Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding
CI
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
BU
Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
CI
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
BU
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
CI
Kiromic BioPharma, Inc. announced that it has received $2 million in funding
CI
EARLY EFFICACY RESULTS SHOW PRIMARY LUNG TUMOR STABILIZATION AND COMPLETE DISAPPEARANCE OF BRAIN METASTASES IN SECOND PATIENT IN KIROMIC BIOPHARMA'S DELTACEL-01 CLINICAL TRIAL
AQ
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
BU
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial
CI
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Kiromic BioPharma : Corporate Presentation
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KRBP Stock
  4. News Kiromic BioPharma, Inc.